In a detailed review of diseases involving deregulation of the ubiquitin–proteasome system, Beck suggests that the development of substrate-specific activator molecules, such as UBA1 in VEXAS syndrome or targeting the proteasome, could be beneficial in the management of these complex diseases. The gene discussed is UBA1; the disease is VEXAS syndrome.